TET2 mutations often occur early during the development of human myeloid malignancies, including PV, ET, MF, myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Here, TET2 is linked to acute myeloid leukemia.